ALBANY, N.Y. (AP) — New York Attorney General Eric Schneiderman is pressing TransUnion and Experian to explain what cybersecurity they have in place to protect sensitive consumer information following a recent breach at Equifax that exposed the data of 143 million Americans.In letters to executives at the two credit monitoring companies, the Democratic attorney general asked them to describe their existing security systems as well as what changes they've made since the Equifax cyberattack."The unprecedented data breach experienced by Equifax Inc.
NYS Entity Status
NYS Filing Date
JULY 18, 2013
NYS DOS ID#
C T CORPORATION SYSTEM
111 EIGHTH AVENUE
NEW YORK, NEW YORK, 10011
NYS Entity Type
FOREIGN BUSINESS CORPORATION
2013 - FIRST SECURITY COMPANY, INC.
Around the Web
- NY AG presses TransUnion, Experian for cybersecurity details
By DAVID KLEPPER, Associated Press - Tuesday Sep 19, 2017
- N.Y. Company Accused of Running Bitcoin Ponzi Scheme
Thursday Sep 21, 2017
The CFTC has accused New York company Gelfman Blueprint of operating a bitcoin-related Ponzi scheme, in the regulator’s first fraud-related action involving the cryptocurrency.
- NY's Hometown Paper Once Again Owned By Chicago Publisher
Tuesday Sep 5, 2017
New York's hometown paper is once again owned by a Chicago-based newspaper holding company, following the 'New York Daily News' sale on Monday to Tronc Inc. In a way, it's like deja vu. Tronc wasformerly Tribune Publishing, the publisher of the 'Chicago Tribune,' which originally created the 'New York Daily News' nearly a century ago.
- NY Times sees jump in digital subscription revenue
By Reuters - Thursday Jul 27, 2017
The New York Times said on Thursday its digital subscription revenue overtook print advertising revenue for the first time — a key milestone in the 166-year old publisher’s efforts to transform itself into a digital media powerhouse. The company’s shares rose as much as 7 percent to their highest since the 2008 financial crisis as...
- Stealthy NY Startup Rocket Pharma Merges With Inotek, Heads to Nasdaq
By Ben Fidler - Tuesday Sep 12, 2017
Rocket Pharmaceuticals, a stealthy gene therapy startup in New York City, has made its first splash. Through a merger with struggling Inotek Pharmaceuticals (NASDAQ: ITEK), Rocket, a company developing treatments for a variety of rare blood diseases, has taken itself public. Rocket shareholders are expected to own 81 percent of the combined company, with Inotek […]